CytoImmune Australia

CytoImmune Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation natural killer (NK) cell therapies for the treatment of cancer. The company utilizes a proprietary platform to engineer NK cells that secrete high levels of soluble IL-15, enhancing their survival and anti-tumor activity within the body. Their lead programs include engineered NK cells targeting acute myeloid leukemia and solid tumors like non-small cell lung cancer. CytoImmune Australia serves as a key regional entity, often facilitating clinical trial activities in the Asia-Pacific region. By leveraging chimeric antigen receptor (CAR) technology and cytokine enhancement, the company aims to provide off-the-shelf cellular immunotherapies that overcome the limitations of current T-cell based treatments.